SCHEMBL16285252

SCHEMBL16285252

CN1CCC(Nc2ccc(C(C)(C)C)cc2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
IDH2 P48735 1/20 0.40
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
FLT3 P36888 1/20 0.38
KAT2B Q92831 2/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
PTK2 Q05397 1/20 0.37
SSTR4 P31391 3/20 0.36
OPRL1 P41146 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND3 P30281 1/20 0.35
CDK6 Q00534 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
HTR1F P30939 1/20 0.35
ACKR3 P25106 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19697062 0.85 POLB (0.43) POLBIDH2KDM4EFLT3KAT2B
SCHEMBL19697059 0.85 HRH3 (0.41) KDM4EGAAHRH3ACKR3
SCHEMBL12779048 0.84 POLB (0.42) POLBIDH2KAT2BHTR2AHTR2C
SCHEMBL16285251 0.83 POLB (0.48) POLBIDH2FLT3KAT2BHTR2A
SCHEMBL19697056 0.83 EPHX2 (0.46) OPRL1
SCHEMBL26407147 0.83 OPRL1 (0.45) HTR2AHTR2CSSTR4OPRL1HRH3
SCHEMBL6928194 0.82 ACKR3 (0.49) POLBKDM4EGAAFLT3KAT2B
SCHEMBL25041352 0.81 ROCK2 (0.49) GAA
SCHEMBL19697061 0.81 PDE3B (0.37) GAAOPRL1
SCHEMBL3023350 0.81 POLB (0.44) POLBIDH2KDM4EGAAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273242-B2 Compound inhibiting activities of BTK and/or JAK3 kinases Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2019-04-30 US disclosed
US-20180051036-A1 COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2018-02-22 US disclosed
US-9840517-B2 Compound inhibiting activities of BTK and/or JAK3 kinases Beijing Hanmi Pharmaceutical Co., Ltd. (CN) 2017-12-12 US disclosed
US-20140364438-A1 TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR HANMI PHARM. CO., LTD. (KR) 2014-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180051036-A1 COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES BTK, JAK3, JAK2 POLB 2153/4885IDH2 4323/4885KDM4E 1460/4885
US-10273242-B2 Compound inhibiting activities of BTK and/or JAK3 kinases BTK, JAK3, JAK2 POLB 2153/4885IDH2 4323/4885KDM4E 1460/4885
US-20140364438-A1 TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR LCK, TYK2, LTK POLB 1538/4885IDH2 2496/4885KDM4E 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.